Phaseline

Targets › PIK3CA

PIK3CA (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform): drug programs, companies and trials

40 programs from 34 companies in 119 trials: 57 Phase 2, 52 Phase 1, 10 Phase 3; Oncology, Other, Metabolic and endocrine; next expected readout Nov 2026.

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). (UniProt, P42336)

Open in Phaseline: the race on PIK3CA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheInavolisib
PI3-kinase p110-alpha subunit inhibitor
PIK3CAPhase 3Breast Cancer; Metastatic Breast Cancer; Metastatic Castration-Resistant Prostate Cancer; PIK3CA-Mutated Cancers …Nov 2026
CelcuityGedatolisib
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 3Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast CancerDec 2026
NovartisAlpelisib (BYL719)
PI3-kinase p110-alpha subunit inhibitor
PIK3CAPhase 3Breast Cancer; Advanced HER2+Breast Cancer; Breast Neoplasms; Advanced Breast Cancer …Jan 2027
Risen (Suzhou) Pharma TechJS105
PIK3CA inhibitor
PIK3CAPhase 3Breast Cancer; Advanced Solid TumorsFeb 2027
Relay TherapeuticsZovegalisib (RLY-2608)
PIK3CA inhibitor
PIK3CAPhase 3PIK3CA Mutation; PIK3CA-Related Overgrowth Spectrum (PROS)Apr 2027
Eli LillyTersolisib (LY4064809/STX-478)
PIK3CA inhibitor
PIK3CAPhase 3Breast NeoplasmsMay 2029
Liling ZhangChidamide
PI3K inhibitor
PIK3CAPhase 2Newly Diagnosed Peripheral T-cell LymphomaDec 2026
The First Affiliated Hospital of Xiamen UniversityChidamide
PI3K inhibitor
PIK3CAPhase 2Peripheral T Cell Lymphoma; Leukemia, Myeloid, Acute; Follicular Lymphoma; Relapsed or Refractory Acute Myeloid LeukemiaDec 2026
National Cancer Institute (NCI)Copanlisib Hydrochloride
PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor
PIK3CA, PIK3CDPhase 2Advanced Lymphoma; Follicular Lymphoma; Malignant Solid Neoplasm; Advanced Malignant Solid Neoplasm …Dec 2026
The First Affiliated Hospital of Xiamen UniversityDuvalisib
Dual phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase 4 (MEK)
PIK3CA, PIK3CB, MAP2K4Phase 2Peripheral T Cell LymphomaDec 2026
Institute of Hematology & Blood Diseases Hospital, ChinaLinperlisib
PI3K inhibitor
PIK3CA, PIK3CB, PIK3DPhase 2Relapsed/Refractory Large B-Cell Lymphoma; Lymphoma, T-CellDec 2026
iOncturaroginolisib (IOA-244)
PI3K inhibitor
PIK3CAPhase 2Uveal Melanoma; Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Myelofibrosis (MF); Solid Tumor, Adult …Jan 2027
Peking Universitylinperlisib
PI3K inhibitor (p110α-selective)
PIK3CAPhase 2Nodal T-follicular Helper Cell LymphomaJan 2027
National Cancer Institute (NCI)Taselisib (GDC-0032)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 2Advanced LymphomaMar 2027
MedSIRMEN1611
Selective PI3K inhibitor with potent activity against PIK3CA catalytic subunit alpha
PIK3CAPhase 2Breast CancerJul 2027
Christian BuskeCopanlisib
PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor
PIK3CA, PIK3CDPhase 2Marginal Zone LymphomaDec 2027
The First Affiliated Hospital with Nanjing Medical UniversityLinperlisib
PI3K inhibitor (specifically PI3K alpha inhibitor)
PIK3CAPhase 2Non-Hodgkin LymphomaDec 2027
Faeth TherapeuticsSerabelisib
PI3-kinase p110-alpha subunit inhibitor
PIK3CAPhase 2Endometrial Cancer; HR+ HER2- Breast CancerSep 2028
University of California, Los AngelesFimepinostat
HDAC and PI3K inhibitor
HDAC, PIK3CAPhase 2Cushing DiseaseJan 2029
Haihe BiopharmaCYH33
PIK3CA inhibitor
PIK3CAPhase 2Ovarian Cancer; PIK3CA-Related Overgrowth Spectrum (PROS)Dec 2029
RestorbioDactolisib (BEZ235)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 2Respiratory Tract Infections; Covid19–
Eli LillyLOXO-783
PIK3CA inhibitor
PIK3CAPhase 1Breast CancerDec 2026
Eli LillySamotolisib (LY3023414)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 1Breast Neoplasms; Endometrial CancerDec 2026
Brown UniversityCopanlisib
PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor
PIK3CA, PIK3CDPhase 1Metastatic Castration-resistant Prostate CancerJan 2027
SovargenPaxalisib (SVG103)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 1Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation …Feb 2027
Yanyan LiuLinperlisib
PI3K inhibitor
PIK3CAPhase 1Peripheral T-cell LymphomaMay 2027
Ensem TherapeuticsETX-636
Pan-mutant-selective PI3Kα inhibitor and degrader
PIK3CAPhase 1Advanced Solid TumorsJun 2027
Vividion TherapeuticsVVD-159642
RAS-PI3Kα inhibitor
KRAS, PIK3CAPhase 1Advanced Solid TumorsAug 2027
The First Hospital of Jilin UniversityLinperlisib
PI3K inhibitor (p110α selective)
PIK3CAPhase 1LymphomaAug 2027
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)BBO-10203
PI3Kα:RAS breaker
PIK3CA, KRAS, NRAS, HRASPhase 1Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung CancerAug 2027
Beijing Tongren HospitalLinperlisib
PI3K inhibitor
PIK3CAPhase 1Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeOct 2027
Totus MedicinesTOS-358
Covalent Phosphoinositide-3-Kinase (PI3K)-alpha inhibitor
PIK3CAPhase 1HR+/HER2-negative Breast CancerDec 2027
Regor PharmaceuticalsRGT-490
PIK3CA inhibitor
PIK3CAPhase 1Breast CancerApr 2028
Changchun GeneScience PharmaceuticalGenSci145
PIK3CA inhibitor
PIK3CAPhase 1Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutatedNov 2028
Sun Yat-sen UniversityLinperlisib
PI3K-alpha inhibitor
PIK3CAPhase 1Peripheral T-cell Lymphoma; Extranodal Natural Killer/T Cell LymphomaDec 2028
Cogent BiosciencesCGT6297
PIK3CA mutant-selective inhibitor
PIK3CAPhase 1PIK3CA MutationsJul 2029
Eli LillySTX-478
mutant-selective PI3Kα inhibitor
PIK3CAPhase 1Breast CancerJul 2030
Recursion PharmaceuticalsREC-7735
PIK3CA-H1047R inhibitor
PIK3CAPhase 1Solid TumorsJan 2031
Dana-Farber Cancer InstituteCopanlisib
PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor
PIK3CA, PIK3CDPhase 1Diffuse Large B Cell Lymphoma–
Eli LillyTersolisib (LY4064809)
PI3K inhibitor
PIK3CAPhase 1Healthy–

Conditions

Breast Cancer (19) Endometrial Cancer (4) Breast Neoplasms (3) PIK3CA-related Overgrowth Spectrum (PROS) (3) Advanced Malignant Solid Neoplasm (3) Advanced Solid Tumors (3) Follicular Lymphoma (3) Advanced Lymphoma (3) Peripheral T-cell Lymphoma (3) Advanced Breast Cancer (2) Insulin Resistance (2) Solid Tumor, Adult (2)

Modalities

small molecule (32), mixed (7), antibody (1)

Companies

Eli Lilly (5) The First Affiliated Hospital of Xiamen University (2) National Cancer Institute (NCI) (2) Novartis (1) Recursion Pharmaceuticals (1) TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1) Totus Medicines (1) Risen (Suzhou) Pharma Tech (1) iOnctura (1) Institute of Hematology & Blood Diseases Hospital, China (1) Liling Zhang (1) Restorbio (1) Brown University (1) Roche (1) Haihe Biopharma (1) Faeth Therapeutics (1) Beijing Tongren Hospital (1) Peking University (1) MedSIR (1) Regor Pharmaceuticals (1)

Related targets

PIK3CB (7) PIK3R1 (5) PIK3CG (5) PIK3CD (4) MTOR (3) KRAS (2) PIK3R2 (2) NRAS (1) HRAS (1) PIK3D (1) MAP2K4 (1) HDAC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.